2024 Research Day
The 2024 DHLRI Research Day will held on Wednesday, October 2, 2024 from 9AM - 3PM. The day's activities will begin on the 1st floor of the Biomedical Research Tower (BRT) with poster presentations, short talks, and lunch, followed by the keynote talk in DHLRI 170.
The keynote speaker for this year is Leslie Leinwand, PhD. 
Dr. Leinwand is a Distinguished Professor of Molecular, Cellular, and Developmental Biology (MCDB) and the Chief Scientific Officer of the BioFrontiers Institute at the University of Colorado Boulder. Her research laboratory focuses on the genetics and molecular physiology of inherited diseases of the heart and particularly how biological sex affects the heart in health and disease. She co-founded Myogen, Inc. (acquired by Gilead Pharmaceuticals), Hiberna, Inc., and MyoKardia, Inc. (acquired by Bristol Myers Sqibb), which develop therapeutics for inherited cardiomyopathies. She is a Fellow of the AAAS, a former MERIT Awardee of the NIH, an Established Investigator of the American Heart Association, and an elected member of the American Academy of Arts and Sciences and the National Academy for Inventors.
Past Events
2023 Research Day
Research Day Recap
.jpg)
On October 10, 2023, the Dorothy M. Davis Heart and Lung Research Institute hosted its 18th Annual Research Day, showcasing the latest projects and achievements of its faculty and students. The event featured ~130 poster presentations and talks by researchers from various areas of cardiovascular and lung disease. Dr. John Warner, CEO of the Wexner Medical Center and Executive Vice President of The Ohio State University, gave remarks and the introduction to keynote speaker Anthony Rosenzweig, MD, a renowned expert in identifying novel mechanism and therapeutic targets in heart failure, using the exercised heart to understand heart health.
Over the past many years, the DHLRI Research Day successes were due, in part, to the unwavering philanthropic support of our friend Charles (Chuck) Webb. Losing a strong advocate of the Institute in June, we pay tribute to his memory and his continuing legacy for his passion of research and social responsibility. His support provided the platform from which to celebrate our best and brightest.
Awards
Distinguished Award Recipients:
- Lorri Fowler - DHLRI Director's Award
- Orlando Simonetti, PhD - Melissa G. Piper Distinguished Mentor Award
- Yingman Liu, PhD - Distinguished Basic Research Staff Award
- Akash Goyal, MD - Distinguished Clinical Fellow Award
- DeeAnn Willis-Berry - Distinguished Administrative Staff Award
- Tatiana Cuellar Gaviria, PhD - Post-Doctoral Scholar of the Year Award
- Vrishti Phadumdeo - Graduate Student of the Year Award
Poster Award Recipients:
- Sally Diep and Aiden George - 1st Place Undergraduate
- Hank Kern - 2nd Place Undergraduate
- Jeniffer Park - 3rd Place Undergraduate
- Aaron Argall - 1st Place Pre-Doctoral
- Benjamin Johnson - 2nd Place Pre-Doctoral
- Sarah Sturgill - 3rd Place Pre-Doctoral
- Elisa Felix Soriano, PhD - 1st Place Post-Doctoral
- Paula Agudelo Garcia, PhD - 2nd Place Post-Doctoral
- Jyotsna Joshi, PhD - 3rd Place Post-Doctoral
- Mithu De, PhD - 1st Place Research Staff
- Ege Kacira - 2nd Place Research Staff
- Magdalena Blaszkiewicz, PhD - 3rd Place Research Staff
- Ian Bentley, MD - 1st Place Clinical Fellow
- Azariyas Challa, MD - 2nd Place Clinical Fellow
- Ashlee Asada, MD - 3rd Place Clinical Fellow
2022 DHLRI Research Day
DHLRI hosted the 17th Annual Research Day on October 19, 2022. Organized by Jenifer Bennett, Research Programs Manager, 2022 Research Day Featured 130 Posters, talks from exceptional trainees, and a highly distinguished keynote talk with a standing room only audience.
The 2022 DHLRI Research Day Keynote Speaker was Joseph C. Wu, MD, PhD. Dr. Wu is the president elect of the American Heart Association, effective July 2022. Dr. Wu is also a physician researcher, Director of the Cardiovascular Institute and Simon H. Stertzer, MD, Professor and Professor of Radiology at Stanford University. His research focuses on the biological mechanisms of patient-specific and disease-specific induced pluripotent stem cells (iPSCs) to understand mechanisms of cardiovascular disease, accelerate drug discovery, develop "clinical trials in a dish" technology, and implement precision medicine for cardiovascular patients.